« Back
Home /
Hexamethylene bisacetamide

Hexamethylene bisacetamide

Item no.	HY-124284-200mg
Manufacturer	MedChem Express
CASRN	3073-59-4
Amount	200 mg
Quantity options	100 mg 10 mM/1 mL 1 ea 200 mg 25 mg 50 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.56
Citations	[1]Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84(5):831-8. [2]Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. [3]Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32(5):791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ [4]Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83. [5]Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15(12):e18024.
Smiles	CC(NCCCCCCNC(C)=O)=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	HMBA
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Akt; Apoptosis; Bcl-2 Family; Epigenetic Reader Domain; MDM-2/p53; NF-κB; Notch; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	200.28
Product Description	Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].
Manufacturer - Research Area	Cancer; Metabolic Disease; Neurological Disease
Solubility	DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Epigenetics; MAPK/ERK Pathway; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-124284-200mg-safety-datasheet.pdf